316 related articles for article (PubMed ID: 29762725)
1. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.
Manohar S; Kompotiatis P; Thongprayoon C; Cheungpasitporn W; Herrmann J; Herrmann SM
Nephrol Dial Transplant; 2019 Jan; 34(1):108-117. PubMed ID: 29762725
[TBL] [Abstract][Full Text] [Related]
2. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
Costa R; Carneiro BA; Agulnik M; Rademaker AW; Pai SG; Villaflor VM; Cristofanilli M; Sosman JA; Giles FJ
Oncotarget; 2017 Jan; 8(5):8910-8920. PubMed ID: 27852042
[TBL] [Abstract][Full Text] [Related]
3. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
4. AKI in Patients Receiving Immune Checkpoint Inhibitors.
Perazella MA; Sprangers B
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
[No Abstract] [Full Text] [Related]
5. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
6. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
7. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T; Takeda Y; Yamashita T; Hamamoto W; Sakamoto Y; Koda H; Kawata S; Matsumoto K; Isomoto H
World J Gastroenterol; 2020 Jan; 26(3):353-365. PubMed ID: 31988594
[TBL] [Abstract][Full Text] [Related]
12. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
[TBL] [Abstract][Full Text] [Related]
13. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
[TBL] [Abstract][Full Text] [Related]
14. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
Shazib MA; Woo SB; Sroussi H; Carvo I; Treister N; Farag A; Schoenfeld J; Haddad R; LeBoeuf N; Villa A
Oral Dis; 2020 Mar; 26(2):325-333. PubMed ID: 31642136
[TBL] [Abstract][Full Text] [Related]
15. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
[TBL] [Abstract][Full Text] [Related]
16. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.
Wang Y; Kong D; Wang C; Chen J; Li J; Liu Z; Li X; Wang Z; Yao G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820967454. PubMed ID: 33084525
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Li H; Xu J; Bai Y; Zhang S; Cheng M; Jin J
Invest New Drugs; 2021 Jun; 39(3):860-870. PubMed ID: 33409896
[TBL] [Abstract][Full Text] [Related]
20. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]